Drugs / JT001
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05802810 | Mar → Sep 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05355077 | May → Aug 2022 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05242042 | Jan 2022 → Mar 2023 | — | Shanghai JunTop Biosciences Co., LTD | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05582629 | Oct 2022 → Feb 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05341609 | Apr → May 2022 | COVID-19 | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT05279235 | Mar → Dec 2022 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05101135 | Nov 2021 → Oct 2022 | type 2 diabetes mellitus | Jeil Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05341609 ↗ |
| Modality | Small molecule | — CHEMBL5219660 ↗ |
| Route | Oral | “JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)” NCT05242042 ↗ |